Press Сentre
Наши новости
Recently, the Government of the Russian Federation approved the Concept of Technological Development until 2030, developed on behalf of Russian President V.V. Putin. The implementation of the Concept should solve the issues of production of high-tech products in the country. It formulates the main directions necessary to achieve technological ...
06.06.2023
Avineuro, a participant of the NeuroNet National Technology Initiative, has completed clinical trials of AVIANDRⓇ, an anti-anxiety medicine. This medicinal product will help people suffering from generalized anxiety disorder or neurological complications of COVID-19. Andrey Ivashchenko, the leader of the NeuroNet working group, gave a speech about ...
29.05.2023
On May 23, a meeting of the Medicinal Chemistry Scientific Council of the Russian Academy of Sciences was held at the Presidium of the Russian Academy of Sciences, chaired by Academician. S.O. Bachurin, where a number of issues related to the development of research in the field of drug development in academic and university centers of Russia were ...
24.05.2023
On April 29 to May 6, representatives of ChemRar Group visited Morocco. The delegation took part in “Medical Expo 2023”, the largest pharmaceutical exhibition in Morocco, to conduct negotiations with representatives of the Ministry of Health of Morocco and the Association of Pharmaceutical Manufacturers. The parties discussed in detail the ...
07.05.2023
On April 26 to 28, the Invest Ethiopia 2023 forum in Addis Ababa was held to attract foreign direct investments to Ethiopia and improve the country's trade and economic relations with foreign states.
Mr. Ahmed Shide, Minister of Finance of Ethiopia, is giving a speech at the Forum
Representatives of ChemRar Group, who visited the Forum, ...
29.04.2023
API-Technology, a part of ChemRar Group, is launching a project to scale up the production of active pharmaceutical ingredients, assist in import substitution and support technological sovereignty of Russia in the field of pharmaceuticals.
Today, when the Russian pharmaceutical industry faces supply chain issues and problems with the purchase of ...
24.04.2023
Favipiravir, developed in Japan to treat influenza and other RNA-viral infections, in 2020–2022 was widely used to treat the novel coronaviral infection in Russia, China, India, Turkey, and many other countries. By now, a host of information has been accumulated in the scientific literature that covers various aspects of favipiravir pharmacology ...
17.01.2023
Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp).
The virus is incapable of developing resistance to favipiravir even with long-term exposure on infected cells, as has been confirmed in clinical trials. ...
27.12.2021
Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group, was rated by Rospatent among Russia’s TOP 100 Inventions for the second half of 2020 and was awarded a diploma for the development of a favipiravir-based formulation Avifavir® — the world's first medicine registered for COVID-19 treatment. In addition to ...
17.06.2021
The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was recognized at the All-Russian Congress on Infectious Diseases.
Last week saw the closing of the 13th All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky “Infectious Diseases in the Modern World: Current ...
08.06.2021
Indonesia registers Russian drug with proven clinical efficacy against coronavirus
Avifavir was the first Favipiravir-based drug in the world approved for the treatment of coronavirus and the first drug registered in Russia to treat coronavirus
Moscow, March 24, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) ...
24.03.2021
Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner Viriom Inc., a San Diego CA-based biotech reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic ...
10.03.2021
Публикации в печатных и электронных СМИ
Видео
Фото
